Omar Faruqe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Omar Faruqe has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Eram Hosen
Department of Microbiology, Shaheed Shamsuzzoha Institute of Biosciences, Affiliated with University of Rajshahi, Rajshahi, Bangladesh
3 shared publications - Nurul Haque Mollah
University of Rajshahi
3 shared publications - Rashed Zaman
Professor Joarder DNA and Chromosome Research Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh
3 shared publications - Alomgir Hossain
Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh
2 shared publications - Asadul Islam
Professor Joarder DNA and Chromosome Research Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh, Bangladesh
2 shared publications - Bayazid Hossen
Bioinformatics Lab, Department of Statistics, University of Rajshahi, Rajshahi 6205, Bangladesh
2 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Elsevier in SSRN Electronic Journal
Inhibitory efficacy and binding mode prediction of natural compounds against pathogenic factors of Alternaria solani: insights from AlphaFold, molecular simulations, and post-simulation analyses
Early blight disease, caused by the fungal pathogen Alternaria solani, is a significant threat to global crop production, particularly affecting widely cultivated crops such as potatoes and tomatoes. The emergence of fungicide resistance and growing environmental concerns have intensified the need for sustainable alternatives to conventional chemical fungicides. This study explores the potential of natural agents to combat A. solani by targeting two key effector proteins, AsCEP112 and AsCEP50, which play critical roles in the infection process. A comprehensive library of 608 natural compounds with known antifungal properties was evaluated using advanced computational approaches. Molecular docking simulation studies identified BR-xanthone A as a highly potent compound, demonstrating superior binding affinities to both the target proteins compared to reference fungicides (Strobilurin and Azoxystrobin). Additionally, Allicin with AsCEP50 and Alpha-mangostin with AsCEP112 exhibited promising binding energies. High-throughput molecular dynamics (MD) simulations assessed stability and interactions, with parameters such as RMSD, RMSF, Rg, SASA, and hydrogen bonds. Post-simulation analyses, including MM-PBSA, PCA, FEL, and PDF, further validated the stability nature of the ligand-protein complexes and revealed probable conformational changes. BR-xanthone A also displayed excellent bioactivity scores and fungicide-likeness, outperforming the reference compounds. This study highlights the potential of natural fungicides as sustainable and effective alternatives to traditional chemical treatments. The selected compound, BR-xanthone A, emerged as a strong candidate for developing next-generation fungicides by specifically targeting fungal virulence factors. The findings provide valuable insights for developing future eco-friendly fungus control agents and enhancing global food security in the face of fungal pathogen threats.
- 20 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessInhibitory efficacy and binding mode prediction of natural compounds against pathogenic factors of Alternaria solani: insights from AlphaFold, molecular simulations, and post-simulation analyses
Early blight disease, caused by the fungal pathogen Alternaria solani, is a significant threat to global crop production, particularly affecting widely cultivated crops such as potatoes and tomatoes. The emergence of fungicide resistance and growing environmental concerns have intensified the need for sustainable alternatives to conventional chemical fungicides. This study explores the potential of natural agents to combat A. solani by targeting two key effector proteins, AsCEP112 and AsCEP50, which play critical roles in the infection process. A comprehensive library of 608 natural compounds with known antifungal properties was evaluated using advanced computational approaches. Molecular docking simulation studies identified BR-xanthone A as a highly potent compound, demonstrating superior binding affinities to both the target proteins compared to reference fungicides (Strobilurin and Azoxystrobin). Additionally, Allicin with AsCEP50 and Alpha-mangostin with AsCEP112 exhibited promising binding energies. High-throughput molecular dynamics (MD) simulations assessed stability and interactions, with parameters such as RMSD, RMSF, Rg, SASA, and hydrogen bonds. Post-simulation analyses, including MM-PBSA, PCA, FEL, and PDF, further validated the stability nature of the ligand-protein complexes and revealed probable conformational changes. BR-xanthone A also displayed excellent bioactivity scores and fungicide-likeness, outperforming the reference compounds. This study highlights the potential of natural fungicides as sustainable and effective alternatives to traditional chemical treatments. The selected compound, BR-xanthone A, emerged as a strong candidate for developing next-generation fungicides by specifically targeting fungal virulence factors. The findings provide valuable insights for developing future eco-friendly fungus control agents and enhancing global food security in the face of fungal pathogen threats.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 5624539
Mechanistic Evaluation of LolA and β ‐Sliding Clamp Inhibition by Silybin and Diclofenac as Gentamicin Adjuvants Against Enteropathogenic Escherichia coli
To address the challenges of antimicrobial resistance, one potential approach is to repurpose existing drugs. In the current study, structurally distinct antibiotics were combined with the repurposed drugs silybin and diclofenac to evaluate the potential of these combinations against resistant bacterial strains. The investigation encompassed in vitro determination of the minimum inhibitory concentration (MIC) and time‐kill kinetics, as well as in vivo assessments of percentage change in body weight, total white blood cell (WBC) count, colitis and edema, histopathological changes, stool scores, and blood culture in an enteropathogenic Escherichia coli (EPEC)‐infected mouse model. Both silybin and diclofenac potentiated the activity of several antibiotics, with gentamicin showing the most promising results. The gentamicin–silybin (Gen + Sily) and gentamicin–diclofenac (Gen + Dic) combinations not only demonstrated sustained antibacterial activity in the time‐kill assay compared with gentamicin monotherapy but also provided greater protection against crypt cell damage and more effectively alleviated colitis and edema in the EPEC‐infected mouse model. In silico molecular docking and 250‐ns molecular dynamics simulations hypothesized two potential targets implicated in antibiotic adjuvant activity: LolA and the β ‐sliding clamp protein. Molecular docking and MM/PBSA analyses indicated that silybin and diclofenac exhibited stronger binding affinities and more favorable total binding free energies toward LolA and the β ‐sliding clamp protein, respectively, than the corresponding reference compounds.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 5624539
Open AccessMechanistic Evaluation of LolA and β ‐Sliding Clamp Inhibition by Silybin and Diclofenac as Gentamicin Adjuvants Against Enteropathogenic Escherichia coli
To address the challenges of antimicrobial resistance, one potential approach is to repurpose existing drugs. In the current study, structurally distinct antibiotics were combined with the repurposed drugs silybin and diclofenac to evaluate the potential of these combinations against resistant bacterial strains. The investigation encompassed in vitro determination of the minimum inhibitory concentration (MIC) and time‐kill kinetics, as well as in vivo assessments of percentage change in body weight, total white blood cell (WBC) count, colitis and edema, histopathological changes, stool scores, and blood culture in an enteropathogenic Escherichia coli (EPEC)‐infected mouse model. Both silybin and diclofenac potentiated the activity of several antibiotics, with gentamicin showing the most promising results. The gentamicin–silybin (Gen + Sily) and gentamicin–diclofenac (Gen + Dic) combinations not only demonstrated sustained antibacterial activity in the time‐kill assay compared with gentamicin monotherapy but also provided greater protection against crypt cell damage and more effectively alleviated colitis and edema in the EPEC‐infected mouse model. In silico molecular docking and 250‐ns molecular dynamics simulations hypothesized two potential targets implicated in antibiotic adjuvant activity: LolA and the β ‐sliding clamp protein. Molecular docking and MM/PBSA analyses indicated that silybin and diclofenac exhibited stronger binding affinities and more favorable total binding free energies toward LolA and the β ‐sliding clamp protein, respectively, than the corresponding reference compounds.
- Open Access
- 21 May 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 1-19
Discovering potential inhibitors against dengue virus NS5 RNA dependent RNA polymerase from local vegetables: a comparative computational study
- 21 May 2025
- Published by Springer Nature in Discover Chemistry
- Vol. 2 (1) , 1-19
Open AccessDiscovering potential inhibitors against dengue virus NS5 RNA dependent RNA polymerase from local vegetables: a comparative computational study
- RetractedOpen Access
- 4 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0302120
In Silico design of a multi-epitope vaccine for Human Parechovirus: Integrating immunoinformatics and computational techniques
Human parechovirus (HPeV) is widely recognized as a severe viral infection affecting infants and neonates. Belonging to the Picornaviridae family, HPeV is categorized into 19 distinct genotypes. Among them, HPeV-1 is the most prevalent genotype, primarily associated with respiratory and digestive symptoms. Considering HPeV’s role as a leading cause of life-threatening viral infections in infants and the lack of effective antiviral therapies, our focus centered on developing two multi-epitope vaccines, namely HPeV-Vax-1 and HPeV-Vax-2, using advanced immunoinformatic techniques. Multi-epitope vaccines have the advantage of protecting against various virus strains and may be preferable to live attenuated vaccines. Using the NCBI database, three viral protein sequences (VP0, VP1, and VP3) from six HPeV strains were collected to construct consensus protein sequences. Then the antigenicity, toxicity, allergenicity, and stability were analyzed after discovering T-cell and linear B-cell epitopes from the protein sequences. The fundamental structures of the vaccines were produced by fusing the selected epitopes with appropriate linkers and adjuvants. Comprehensive physicochemical, antigenic, allergic assays, and disulfide engineering demonstrated the effectiveness of the vaccines. Further refinement of secondary and tertiary models for both vaccines revealed promising interactions with toll-like receptor 4 (TLR4) in molecular docking, further confirmed by molecular dynamics simulation. In silico immunological modeling was employed to assess the vaccine’s capacity to stimulate an immune reaction. In silico immunological simulations were employed to evaluate the vaccines’ ability to trigger an immune response. Codon optimization and in silico cloning analyses showed that Escherichia coli (E. coli) was most likely the host for the candidate vaccines. Our findings suggest that these multi-epitope vaccines could be the potential HPeV vaccines and are recommended for further wet-lab investigation.
- 4 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0302120
RetractedOpen AccessIn Silico design of a multi-epitope vaccine for Human Parechovirus: Integrating immunoinformatics and computational techniques
Human parechovirus (HPeV) is widely recognized as a severe viral infection affecting infants and neonates. Belonging to the Picornaviridae family, HPeV is categorized into 19 distinct genotypes. Among them, HPeV-1 is the most prevalent genotype, primarily associated with respiratory and digestive symptoms. Considering HPeV’s role as a leading cause of life-threatening viral infections in infants and the lack of effective antiviral therapies, our focus centered on developing two multi-epitope vaccines, namely HPeV-Vax-1 and HPeV-Vax-2, using advanced immunoinformatic techniques. Multi-epitope vaccines have the advantage of protecting against various virus strains and may be preferable to live attenuated vaccines. Using the NCBI database, three viral protein sequences (VP0, VP1, and VP3) from six HPeV strains were collected to construct consensus protein sequences. Then the antigenicity, toxicity, allergenicity, and stability were analyzed after discovering T-cell and linear B-cell epitopes from the protein sequences. The fundamental structures of the vaccines were produced by fusing the selected epitopes with appropriate linkers and adjuvants. Comprehensive physicochemical, antigenic, allergic assays, and disulfide engineering demonstrated the effectiveness of the vaccines. Further refinement of secondary and tertiary models for both vaccines revealed promising interactions with toll-like receptor 4 (TLR4) in molecular docking, further confirmed by molecular dynamics simulation. In silico immunological modeling was employed to assess the vaccine’s capacity to stimulate an immune reaction. In silico immunological simulations were employed to evaluate the vaccines’ ability to trigger an immune response. Codon optimization and in silico cloning analyses showed that Escherichia coli (E. coli) was most likely the host for the candidate vaccines. Our findings suggest that these multi-epitope vaccines could be the potential HPeV vaccines and are recommended for further wet-lab investigation.
- Open Access
Exploring the Therapeutic Potential of Petiveria alliacea L. Phytochemicals: A Computational Study on Inhibiting SARS-CoV-2’s Main Protease (Mpro)
The outbreak of SARS-CoV-2, also known as the COVID-19 pandemic, is still a critical risk factor for both human life and the global economy. Although, several promising therapies have been introduced in the literature to inhibit SARS-CoV-2, most of them are synthetic drugs that may have some adverse effects on the human body. Therefore, the main objective of this study was to carry out an in-silico investigation into the medicinal properties of Petiveria alliacea L. (P. alliacea L.)-mediated phytocompounds for the treatment of SARS-CoV-2 infections since phytochemicals have fewer adverse effects compared to synthetic drugs. To explore potential phytocompounds from P. alliacea L. as candidate drug molecules, we selected the infection-causing main protease (Mpro) of SARS-CoV-2 as the receptor protein. The molecular docking analysis of these receptor proteins with the different phytocompounds of P. alliacea L. was performed using AutoDock Vina. Then, we selected the three top-ranked phytocompounds (myricitrin, engeletin, and astilbin) as the candidate drug molecules based on their highest binding affinity scores of −8.9, −8.7 and −8.3 (Kcal/mol), respectively. Then, a 100 ns molecular dynamics (MD) simulation study was performed for their complexes with Mpro using YASARA software, computed RMSD, RMSF, PCA, DCCM, MM/PBSA, and free energy landscape (FEL), and found their almost stable binding performance. In addition, biological activity, ADME/T, DFT, and drug-likeness analyses exhibited the suitable pharmacokinetics properties of the selected phytocompounds. Therefore, the results of this study might be a useful resource for formulating a safe treatment plan for SARS-CoV-2 infections after experimental validation in wet-lab and clinical trials.
Open AccessExploring the Therapeutic Potential of Petiveria alliacea L. Phytochemicals: A Computational Study on Inhibiting SARS-CoV-2’s Main Protease (Mpro)
The outbreak of SARS-CoV-2, also known as the COVID-19 pandemic, is still a critical risk factor for both human life and the global economy. Although, several promising therapies have been introduced in the literature to inhibit SARS-CoV-2, most of them are synthetic drugs that may have some adverse effects on the human body. Therefore, the main objective of this study was to carry out an in-silico investigation into the medicinal properties of Petiveria alliacea L. (P. alliacea L.)-mediated phytocompounds for the treatment of SARS-CoV-2 infections since phytochemicals have fewer adverse effects compared to synthetic drugs. To explore potential phytocompounds from P. alliacea L. as candidate drug molecules, we selected the infection-causing main protease (Mpro) of SARS-CoV-2 as the receptor protein. The molecular docking analysis of these receptor proteins with the different phytocompounds of P. alliacea L. was performed using AutoDock Vina. Then, we selected the three top-ranked phytocompounds (myricitrin, engeletin, and astilbin) as the candidate drug molecules based on their highest binding affinity scores of −8.9, −8.7 and −8.3 (Kcal/mol), respectively. Then, a 100 ns molecular dynamics (MD) simulation study was performed for their complexes with Mpro using YASARA software, computed RMSD, RMSF, PCA, DCCM, MM/PBSA, and free energy landscape (FEL), and found their almost stable binding performance. In addition, biological activity, ADME/T, DFT, and drug-likeness analyses exhibited the suitable pharmacokinetics properties of the selected phytocompounds. Therefore, the results of this study might be a useful resource for formulating a safe treatment plan for SARS-CoV-2 infections after experimental validation in wet-lab and clinical trials.
- Open Access
- 22 May 2024
- Published by Springer Nature in Archives of Microbiology
- Vol. 206 (6) , 1
Correction to: Modulating the antibacterial effect of the existing antibiotics along with repurposing drug metformin
- 22 May 2024
- Published by Springer Nature in Archives of Microbiology
- Vol. 206 (6) , 1
Open AccessCorrection to: Modulating the antibacterial effect of the existing antibiotics along with repurposing drug metformin
- Open Access
- 1 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 483
Characterization of Plant-Derived Natural Inhibitors of Dipeptidyl Peptidase-4 as Potential Antidiabetic Agents: A Computational Study
Diabetes, characterized by elevated blood sugar levels, poses significant health and economic risks, correlating with complications like cardiovascular disease, kidney failure, and blindness. Dipeptidyl peptidase-4 (DPP-4), also referred to as T-cell activation antigen CD26 (EC 3.4.14.5.), plays a crucial role in glucose metabolism and immune function. Inhibiting DPP-4 was anticipated as a potential new therapy for diabetes. Therefore, identification of plant-based natural inhibitors of DPP-4 would help in eradicating diabetes worldwide. Here, for the identification of the potential natural inhibitors of DPP-4, we developed a phytochemicals library consisting of over 6000 phytochemicals detected in 81 medicinal plants that exhibited anti-diabetic potency. The library has been docked against the target proteins, where isorhamnetin, Benzyl 5-Amino-5-deoxy-2,3-O-isopropyl-alpha-D-mannofuranoside (DTXSID90724586), and 5-Oxo-7-[4-(trifluoromethyl) phenyl]-4H,6H,7H-[1,2]thiazolo[4,5-b]pyridine 3-carboxylic acid (CHEMBL3446108) showed binding affinities of −8.5, −8.3, and −8.3 kcal/mol, respectively. These compounds exhibiting strong interactions with DPP-4 active sites (Glu205, Glu206, Tyr547, Trp629, Ser630, Tyr662, His740) were identified. ADME/T and bioactivity predictions affirmed their pharmacological safety. Density functional theory calculations assessed stability and reactivity, while molecular dynamics simulations demonstrated persistent stability. Analyzing parameters like RMSD, RG, RMSF, SASA, H-bonds, MM-PBSA, and FEL confirmed stable protein–ligand compound formation. Principal component analysis provided structural variation insights. Our findings suggest that those compounds might be possible candidates for developing novel inhibitors targeting DPP-4 for treating diabetes.
- 1 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 483
Open AccessCharacterization of Plant-Derived Natural Inhibitors of Dipeptidyl Peptidase-4 as Potential Antidiabetic Agents: A Computational Study
Diabetes, characterized by elevated blood sugar levels, poses significant health and economic risks, correlating with complications like cardiovascular disease, kidney failure, and blindness. Dipeptidyl peptidase-4 (DPP-4), also referred to as T-cell activation antigen CD26 (EC 3.4.14.5.), plays a crucial role in glucose metabolism and immune function. Inhibiting DPP-4 was anticipated as a potential new therapy for diabetes. Therefore, identification of plant-based natural inhibitors of DPP-4 would help in eradicating diabetes worldwide. Here, for the identification of the potential natural inhibitors of DPP-4, we developed a phytochemicals library consisting of over 6000 phytochemicals detected in 81 medicinal plants that exhibited anti-diabetic potency. The library has been docked against the target proteins, where isorhamnetin, Benzyl 5-Amino-5-deoxy-2,3-O-isopropyl-alpha-D-mannofuranoside (DTXSID90724586), and 5-Oxo-7-[4-(trifluoromethyl) phenyl]-4H,6H,7H-[1,2]thiazolo[4,5-b]pyridine 3-carboxylic acid (CHEMBL3446108) showed binding affinities of −8.5, −8.3, and −8.3 kcal/mol, respectively. These compounds exhibiting strong interactions with DPP-4 active sites (Glu205, Glu206, Tyr547, Trp629, Ser630, Tyr662, His740) were identified. ADME/T and bioactivity predictions affirmed their pharmacological safety. Density functional theory calculations assessed stability and reactivity, while molecular dynamics simulations demonstrated persistent stability. Analyzing parameters like RMSD, RG, RMSF, SASA, H-bonds, MM-PBSA, and FEL confirmed stable protein–ligand compound formation. Principal component analysis provided structural variation insights. Our findings suggest that those compounds might be possible candidates for developing novel inhibitors targeting DPP-4 for treating diabetes.
- 23 March 2024
- Published by Springer Nature in Archives of Microbiology
- Vol. 206 (4) , 1-18
Modulating the antibacterial effect of the existing antibiotics along with repurposing drug metformin
Owing to the extensive prevalence of resistant bacteria to numerous antibiotic classes, antimicrobial resistance (AMR) poses a well-known hazard to world health. As an alternate approach in the field of antimicrobial drug discovery, repurposing the available medications which are also called antibiotic resistance breakers has been pursued for the treatment of infections with antimicrobial resistance pathogens. In this study, we used Haloperidol, Metformin and Hydroxychloroquine as repurposing drugs in in vitro (Antibacterial Antibiotic Sensitivity Test and Minimum Inhibitory Concentration-MIC) and in vivo (Shigellosis in Swiss albino mice) tests in combination with traditional antibiotics (Oxytetracycline, Erythromycin, Doxycycline, Gentamicin, Ampicillin, Chloramphenicol, and Penicillin) against a group of AMR resistance bacteria (Bacillus cereus, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Shigella boydii). After observing the results of the conducted in vitro experiments we studied the effects of the above non antibiotic drugs in combination with the said antibiotics. As an repurposing adjuvant antibiotic drug, Metformin exhibited noteworthy activity in almost all in vitro, in vivo and in silico tests (Zone of inhibition for 30 to 43 mm for E.coli in combination with Doxycycline; MIC value decreased 50 µM to 0.781 µM with Doxycycline on S. boydii).In rodents Doxycycline and Metformin showed prominent against Shigellosis in White blood cell count (6.47 ± 0.152 thousand/mm3) and Erythrocyte sedimentation rate (10.5 ± 1.73 mm/hr). Our findings indicated that Metformin and Doxycycline combination has a crucial impact on Shigellosis. The molecular docking study was performed targeting the Acriflavine resistance protein B (AcrB) (PDB ID: 4CDI) and MexA protein (PDB ID: 6IOK) protein with Metformin (met8) drug which showed the highest binding energy with − 6.4 kcal/mol and − 5.5 kcal/mol respectively. Further, molecular dynamics simulation revealed that the docked complexes were relatively stable during the 100 ns simulation period. This study suggest Metformin and other experimented drugs can be used as adjuvants boost up antibiosis but further study is needed to find out the safety and efficacy of this non-antibiotic drug as potent antibiotic adjuvant.
- 23 March 2024
- Published by Springer Nature in Archives of Microbiology
- Vol. 206 (4) , 1-18
Modulating the antibacterial effect of the existing antibiotics along with repurposing drug metformin
Owing to the extensive prevalence of resistant bacteria to numerous antibiotic classes, antimicrobial resistance (AMR) poses a well-known hazard to world health. As an alternate approach in the field of antimicrobial drug discovery, repurposing the available medications which are also called antibiotic resistance breakers has been pursued for the treatment of infections with antimicrobial resistance pathogens. In this study, we used Haloperidol, Metformin and Hydroxychloroquine as repurposing drugs in in vitro (Antibacterial Antibiotic Sensitivity Test and Minimum Inhibitory Concentration-MIC) and in vivo (Shigellosis in Swiss albino mice) tests in combination with traditional antibiotics (Oxytetracycline, Erythromycin, Doxycycline, Gentamicin, Ampicillin, Chloramphenicol, and Penicillin) against a group of AMR resistance bacteria (Bacillus cereus, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Shigella boydii). After observing the results of the conducted in vitro experiments we studied the effects of the above non antibiotic drugs in combination with the said antibiotics. As an repurposing adjuvant antibiotic drug, Metformin exhibited noteworthy activity in almost all in vitro, in vivo and in silico tests (Zone of inhibition for 30 to 43 mm for E.coli in combination with Doxycycline; MIC value decreased 50 µM to 0.781 µM with Doxycycline on S. boydii).In rodents Doxycycline and Metformin showed prominent against Shigellosis in White blood cell count (6.47 ± 0.152 thousand/mm3) and Erythrocyte sedimentation rate (10.5 ± 1.73 mm/hr). Our findings indicated that Metformin and Doxycycline combination has a crucial impact on Shigellosis. The molecular docking study was performed targeting the Acriflavine resistance protein B (AcrB) (PDB ID: 4CDI) and MexA protein (PDB ID: 6IOK) protein with Metformin (met8) drug which showed the highest binding energy with − 6.4 kcal/mol and − 5.5 kcal/mol respectively. Further, molecular dynamics simulation revealed that the docked complexes were relatively stable during the 100 ns simulation period. This study suggest Metformin and other experimented drugs can be used as adjuvants boost up antibiosis but further study is needed to find out the safety and efficacy of this non-antibiotic drug as potent antibiotic adjuvant.
- Open Access
- 1 January 2024
- Published by Wiley in BioMed Research International
- Vol. 2024 (1) , 6810200
Integrated Gene Expression Data‐Driven Identification of Molecular Signatures, Prognostic Biomarkers, and Drug Targets for Glioblastoma
Glioblastoma (GBM) is a highly prevalent and deadly brain tumor with high mortality rates, especially among adults. Despite extensive research, the underlying mechanisms driving its progression remain poorly understood. Computational analysis offers a powerful approach to explore potential prognostic biomarkers, drug targets, and therapeutic agents for GBM. In this study, we utilized three gene expression datasets from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) associated with GBM progression. Our goal was to uncover key molecular players implicated in GBM pathogenesis and potential avenues for targeted therapy. Analysis of the gene expression datasets revealed a total of 78 common DEGs that are potentially involved in GBM progression. Through further investigation, we identified nine hub DEGs that are highly interconnected in protein–protein interaction (PPI) networks, indicating their central role in GBM biology. Gene Ontology (GO) and pathway enrichment analyses provided insights into the biological processes and immunological pathways influenced by these DEGs. Among the nine identified DEGs, survival analysis demonstrated that increased expression of GMFG correlated with decreased patient survival rates in GBM, suggesting its potential as a prognostic biomarker and preventive target for GBM. Furthermore, molecular docking and ADMET analysis identified two compounds from the NIH clinical collection that showed promising interactions with the GMFG protein. Besides, a 100 nanosecond molecular dynamics (MD) simulation evaluated the conformational changes and the binding strength. Our study highlights the potential of GMFG as both a prognostic biomarker and a therapeutic target for GBM. The identification of GMFG and its associated pathways provides valuable insights into the molecular mechanisms driving GBM progression. Moreover, the identification of candidate compounds with potential interactions with GMFG offers exciting possibilities for targeted therapy development. However, further laboratory experiments are required to validate the role of GMFG in GBM pathogenesis and to assess the efficacy of potential therapeutic agents targeting this molecule.
- 1 January 2024
- Published by Wiley in BioMed Research International
- Vol. 2024 (1) , 6810200
Open AccessIntegrated Gene Expression Data‐Driven Identification of Molecular Signatures, Prognostic Biomarkers, and Drug Targets for Glioblastoma
Glioblastoma (GBM) is a highly prevalent and deadly brain tumor with high mortality rates, especially among adults. Despite extensive research, the underlying mechanisms driving its progression remain poorly understood. Computational analysis offers a powerful approach to explore potential prognostic biomarkers, drug targets, and therapeutic agents for GBM. In this study, we utilized three gene expression datasets from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) associated with GBM progression. Our goal was to uncover key molecular players implicated in GBM pathogenesis and potential avenues for targeted therapy. Analysis of the gene expression datasets revealed a total of 78 common DEGs that are potentially involved in GBM progression. Through further investigation, we identified nine hub DEGs that are highly interconnected in protein–protein interaction (PPI) networks, indicating their central role in GBM biology. Gene Ontology (GO) and pathway enrichment analyses provided insights into the biological processes and immunological pathways influenced by these DEGs. Among the nine identified DEGs, survival analysis demonstrated that increased expression of GMFG correlated with decreased patient survival rates in GBM, suggesting its potential as a prognostic biomarker and preventive target for GBM. Furthermore, molecular docking and ADMET analysis identified two compounds from the NIH clinical collection that showed promising interactions with the GMFG protein. Besides, a 100 nanosecond molecular dynamics (MD) simulation evaluated the conformational changes and the binding strength. Our study highlights the potential of GMFG as both a prognostic biomarker and a therapeutic target for GBM. The identification of GMFG and its associated pathways provides valuable insights into the molecular mechanisms driving GBM progression. Moreover, the identification of candidate compounds with potential interactions with GMFG offers exciting possibilities for targeted therapy development. However, further laboratory experiments are required to validate the role of GMFG in GBM pathogenesis and to assess the efficacy of potential therapeutic agents targeting this molecule.
- Open Access
- 15 September 2023
- Published by Wiley in International Journal of Alzheimer's Disease
- Vol. 2023, 1-19
Unveiling Neuroprotective Potential of Spice Plant-Derived Compounds against Alzheimer’s Disease: Insights from Computational Studies
Alzheimer’s disease (AD) is a serious threat to the global health care system and is brought on by a series of factors that cause neuronal dysfunction and impairment in memory and cognitive decline. This study investigated the therapeutic potential of phytochemicals that belong to the ten regularly used spice plants, based on their binding affinity with AD-associated proteins. Comprehensive docking studies were performed using AutoDock Vina in PyRx followed by molecular dynamic (MD) simulations using AMBER 14. The docking study of the chosen molecules revealed the binding energies of their interactions with the target proteins, while MD simulations were carried out to verify the steadiness of bound complexes. Through the Lipinski filter and admetSAR analysis, the chosen compounds’ pharmacokinetic characteristics and drug likeness were also examined. The pharmacophore mapping study was also done and analyzed for best selected molecules. Additionally, principal component analysis (PCA) was used to examine how the general motion of the protein changed. The results showed quercetin and myricetin to be potential inhibitors of AChE and alpha-amyrin and beta-chlorogenin to be potential inhibitors of BuChE, exhibiting best binding energies comparable to those of donepezil, used as a positive control. The multiple descriptors from the simulation study, root mean square deviation (RMSD), root mean square fluctuation (RMSF), hydrogen bond, radius of gyration (Rg), and solvent-accessible surface areas (SASA), confirm the stable nature of the protein-ligand complexes. Molecular mechanic Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations indicated the energetically favorable binding of the ligands to the protein. Finally, according to pharmacokinetic properties and drug likeness, characteristics showed that quercetin and myricetin for AChE and alpha-amyrin and beta-chlorogenin for BuChE were found to be the most effective agents for treating the AD.
- 15 September 2023
- Published by Wiley in International Journal of Alzheimer's Disease
- Vol. 2023, 1-19
Open AccessUnveiling Neuroprotective Potential of Spice Plant-Derived Compounds against Alzheimer’s Disease: Insights from Computational Studies
Alzheimer’s disease (AD) is a serious threat to the global health care system and is brought on by a series of factors that cause neuronal dysfunction and impairment in memory and cognitive decline. This study investigated the therapeutic potential of phytochemicals that belong to the ten regularly used spice plants, based on their binding affinity with AD-associated proteins. Comprehensive docking studies were performed using AutoDock Vina in PyRx followed by molecular dynamic (MD) simulations using AMBER 14. The docking study of the chosen molecules revealed the binding energies of their interactions with the target proteins, while MD simulations were carried out to verify the steadiness of bound complexes. Through the Lipinski filter and admetSAR analysis, the chosen compounds’ pharmacokinetic characteristics and drug likeness were also examined. The pharmacophore mapping study was also done and analyzed for best selected molecules. Additionally, principal component analysis (PCA) was used to examine how the general motion of the protein changed. The results showed quercetin and myricetin to be potential inhibitors of AChE and alpha-amyrin and beta-chlorogenin to be potential inhibitors of BuChE, exhibiting best binding energies comparable to those of donepezil, used as a positive control. The multiple descriptors from the simulation study, root mean square deviation (RMSD), root mean square fluctuation (RMSF), hydrogen bond, radius of gyration (Rg), and solvent-accessible surface areas (SASA), confirm the stable nature of the protein-ligand complexes. Molecular mechanic Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations indicated the energetically favorable binding of the ligands to the protein. Finally, according to pharmacokinetic properties and drug likeness, characteristics showed that quercetin and myricetin for AChE and alpha-amyrin and beta-chlorogenin for BuChE were found to be the most effective agents for treating the AD.